Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 104, Issue 3, 2009, Pages 605-616

  Ferrara, Francesca ^a   Ventura, Paolo ^a   Vegetti, Alberto ^a   Guido, Maria ^b   Abbati, Gianluca ^a   Corradini, Elena ^a   Fattovich, Giovanna ^c   Ferrari, Carlo ^d   Tagliazucchi, Mara ^a   Carbonieri, Anna ^a   Orlandini, Alessandra ^c   Fagiuoli, Stefano ^b   Boninsegna, Sara ^b   Minola, Eliseo ^e   Rizzo, Giovanna ^e   Belussi, Fabio ^f   Felder, Martina ^g   Massari, Marco ^h   Pozzato, Gabriele ⁱ   Bonetto, Stefania ⁱ   Rovere, Pierangelo ^j   Sardini, Carla ^a   Borghi, Athos ^a   Zeneroli, Maria Luisa ^a   Toniutto, Pierluigi ^k   Rossi, Elisabetta ^k   Pietrangelo, Antonello ^a   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f SS Giovanni e Paolo Hospital   (Italy)

^g CENTRAL HOSPITAL OF BOLZANO   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF TRIESTE   (Italy)

^j Legnago Hospital   (Italy)

^k UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; PEGINTERFERON; PEGINTERFERON 2A; PEGINTERFERON 2B; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FERRITIN BLOOD LEVEL; FIBROSIS; HEMOLYSIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRON BLOOD LEVEL; KUPFFER CELL; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDEROSIS; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; FERRITINS; HEMOLYSIS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; IRON; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TRANSFERRIN; TREATMENT OUTCOME;

EID: 62049086128     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.126     Document Type: Article

References (43)

1. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
2. Di Bisceglie AM, Axiotis CA, Hoofnagle JH et al. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-13.
3. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-68.
4. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509-23.
5. Vari IS, Balkau B, Kettaneh A et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007;30:1795-801.
6. Forouhi NG, Harding AH, Allison M et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007;50:949-56.
7. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
8. Lecube A, Hernandez C, Genesca J et al. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care 2004;27:2669-75.
9. Asselah T, Rubbia-Brandt L, Marcellin P et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:123-30.
10. Jarvis SM, B orn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123:1587-92.
11. Weiss G, Umlauft F, Urbanek M et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999;180:1452-8.
12. Aguilar-Martinez P, Jeanjean P, Masmejan C et al. Simple and rapid detection for the newly described mutations in the HLA-H gene. Blood 1997;89:1835-6.
13. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
14. Deugnier YM, Loreal O, Turlin B et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992;102:2050-9.
15. Guyader D, Thirouard AS, Erdtmann L et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 2007;46:587-95.
16. Hosmer D, Lemeshow S. Applied Logistic Regression. Wiley: New York, 2000.
17. Cassanelli S, Pignatti E, Montosi G et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol 2001;34:523-8.
18. Valenti L, Pulixi EA, Arosio P et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007;92:1037-42.
19. Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 2002;97:1-4.
20. Alexander J, Kowdley KV. Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction? Gastroenterology 2006;131:1635-8.
21. Distante S, Bjoro K, Hellum KB et al. Raised serum ferritin predicts non response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75.
22. Fujita N, Sugimoto R, Urawa N et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1886-93.
23. Coelho-Borges S, Cheinquer H, Chinquer N et al. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. Am J Gastroenterol 2002;97:1570-2.
24. Rulyak S, Eng S, Patel K et al. Relationship between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005;100:332-7.
25. Hofer H, Osterreicher C, Jessner W et al. Hepatic iron does not predict response ti standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004;40:1018-22.
26. Van Vlierbergh H, Delanghe JR, De Vos M et al. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001;34:911-6.
27. Di Bisceglie AM, Bacon BR, Kleiner DE et al. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994;21:1109-12.
28. Fiel MI, Schiano TD, Guido M et al. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am J Clin Pathol 2000;113:35-9.
29. Canonico PG, Kastello MD, Spears CT et al. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984;74:155-62.
30. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002;99:3505-16.
31. Feelders RA, Vreugdenhil G, Eggermont AM et al. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 1998;28:520-7.
32. Recalcati S, Taramelli D, Conte D et al. Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by inflammatory cytokines: role of selective iron regulatory protein-2 downregulation. Blood 1998;91:1059-66.
33. Stam TC, Swaak AJ, Kruit WH et al. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest 2002;32 (Suppl 1):79-83.
34. Cazzola M, Bergamaschi G, Dezza L et al. The origin of serum ferritin in acquired transfusional iron overload in adults. Studies with concanavalin A-sepharose absorption. Haematologica 1982;67:817-24.
35. Barton AL, Banner BF, Cable EE et al. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995;103:419-24.
36. Weiss G, Wernerfelmayer G, Werner ER et al. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994;180:969-76.
37. Olynyk JK, Clarke SL. Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells. J Gastroenterol Hepatol 2001;16:438-44.
38. Boucher E, Bourienne A, Adams P et al. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997;41:115-20.
39. Sebastiani G, Vario A, Ferrari A et al. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hepat 2006;13:199-205.
40. Ha que S, Chandra B, Gerber MA et al. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol 1996;27:1277-81.
41. Brunt EM, Olynyk JK, Britton RS et al. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol 2000;95:1788-93.
42. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 1996;16:13-30.
43. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-44.